SGS expands E&L testing services at New Jersey facility

By Dani Bancroft contact

- Last updated on GMT

SGS expands E&L testing services at New Jersey facility

Related tags: Clinical trial

SGS SA has expanded its Extractables and Leachables testing services with new equipment and specialist analysts at its facility in New Jersey, US.

Extractables and Leachables (E&L) studies are needed to identify and quantify any impurities which can contaminate​ drug products from packaging, equipment or single-use systems.

SGS has purchased and installed two new instruments that are specialised in detecting these kind of contaminants at its Fairfield lab in New Jersey.

These are a liquid chromatography-tandem mass spectrometer (LC-MS-MS) and a gas chromatography-mass spectrometer (GC-MS), which are used to identify traces of unknown extractable compounds.

In addition, the Swiss firm is hiring extra analysts specialising in E&L testing to operate the new equipment and contribute to the expansion of its quality assurance and control services.

“SGS has seen a rise in the demand for services in this area, and we have invested significantly across our global network to ensure that we can maintain our strong reputation for extractables and leachables testing expertise,”​ said Kelly Bertrand, General Manager of SGS’s Fairfield facility.

High throughput 

SGS claims both of the new instruments have enough space for the user head, high resolution and high throughput systems.

An LC-MS-MS offers superior specificity​ compared to that of traditional immunoassays and high performance/pressure liquid chromatography (HPLC).

Additionally, the tech has a higher throughput than the GC-MS, requiring a smaller amount of material needed for testing.

The Fairfield lab offers the instruments use for E&L testing of final pharmaceutical packaging, single-use systems and medical devices.

Bertrand added “The additional capabilities we have now at Fairfield allow us to overcome greater analytical challenges for our existing clients, and ensure we can remain competitive and have the capacity to attract new customers.”


SGS employs over 90,000 with 21 labs that provide contract analytical testing services across North America, the EU and Asia​.

The firm also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance and regulatory consultancy.

This E&L investment at the Fairfield laboratory follows the opening​ of a new global Center of Excellence for Extractable Studies and Impurities Profiling in Wiesbaden, Germany.

Image: The Fairfield Lab, New Jersey (SGS SA/The Bannett GROUP)

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more